María Eugenia de la Morena-Barrio, PhD

PhD
Servicio de Hematología, Hospital General Universitario Morales Messeguer, Centro Regional de Hemodonación, Universidad de Murcia, Universidad de Murcia, IMIB-Pascual Parrilla, CIBERER-ISCIII
Murcia, Murcia, Spain

Principal investigator at the University of Murcia, Spain, in the Experimental Hematology and Oncology Group. Graduated in Biochemistry in 2008 and received an International PhD in Medicine from the University of Murcia in 2013, awarded with an extraordinary doctoral prize and recognized as the best thesis by the Robles Chillida Foundation. In 2012, she completed a training period at the Catholic University of Leuven, Belgium under the supervision of Dr. Freson and Dr. Jaeken on congenital disorders of glycosylation.

Author of 83 articles, h-index of 20, i10-index of 46, with a total of 981 citations. Holds 3 patents and founded a technological-based company in 2020 specializing in genetic sequencing of long reads. Member of the research team in 25 competitive projects, principal investigator of 4 of them. Supervised of three doctoral theses. Selected in 2020 by international societies EHA/ASH for the Translational Research Training in Hematology (TRTH) international leadership program. Serves as associate editor for 2 journals, guest editor for 2 journals, and reviewer for 12 JCR journals. Member of the Spanish Network on Rare Diseases (CIBERER), the Spanish Society of Thrombosis and Hemostasis (SETH), the European Hematology Association (EHA), the American Society of Hematology (ASH), and the International Society of Thrombosis and Haemostasis (ISTH). Specializes in hemostasis and in congenital disorders of glycosylation; focusing on molecular bases and mechanisms involved in thrombotic diseases (antithrombin deficiency) and hemorrhagic disorders (congenital Factor XI deficiency).

Holds 35 research awards, including recognition from the Royal Academy of Medicine and the Royal Spanish Foundation for Hemophilia Victoria Eugenia.

Presentation(s):

• OC 08.3 - Insights of retrotransposon insertions in antithrombin deficiency lead to a complete study of the landscape of mobile elements throughout the whole genome with nanopore sequencing

  Saturday, June 22, 2024
  13:30 – 13:45 ICT

• OC 08.4 - Landscape of antisense genes in the human genome and identification of new human hepatic antisense RNAs by long-read sequencing. Relevance in hemostasis.

  Saturday, June 22, 2024
  13:45 – 14:00 ICT

• OC 12.3 - MIR5683 predicts venous thromboembolism in advanced gastric cancer through regulation of thrombin generation, fibrinolysis and endothelial TFPI expression

  Sunday, June 23, 2024
  10:00 – 10:15 ICT

• PB0477 - Antithrombin deficiency in women: risk factors and management. A single-center experience

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0316 - De novo and recurrent SERPINC1 variants in antithrombin deficiency: origin, expansion and clinical implications.

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0314 - Identification of Congenital Disorders of Glycosylation among Patients with Antithrombin Deficiency: Enhancing Diagnosis and its Therapeutic Implications.

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0319 - Reduced plasma selenoprotein P is associated with type I antithrombin deficiency and prothrombotic clot phenotype

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0317 - Unravelling the disulfide-bonded states of antithrombin: Implications for anticoagulant activity

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• SOA 26.4 - Non-hemostatic roles of anticoagulant proteins

  Wednesday, June 26, 2024
  08:30 – 09:45 ICT

• OC 76.3 - Landscape of natural variants affecting the N-glycosylation of antithrombin: biological and clinical impact

  Wednesday, June 26, 2024
  10:45 – 11:00 ICT